uniQure(QURE) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $16.1 million, a decrease from $27.1 million in 2024, primarily due to a $10.7 million decrease in collaboration revenue and a $6.1 million decrease in contract manufacturing revenues, offset by a $5.8 million increase in license revenues [27] - Research and development expenses were $140.7 million for 2025, down from $143.8 million in 2024, driven by a $26 million decrease in total other research and development expenses [28] - Cash, cash equivalents, and investment securities totaled $622.5 million as of December 31, 2025, compared to $367.5 million as of December 31, 2024, primarily due to proceeds of approximately $404.2 million raised from public offerings [30] Business Line Data and Key Metrics Changes - AMT-130 showed a statistically significant 75% slowing of disease progression in Huntington's disease as measured by the Composite Unified Huntington's Disease Rating Scale [7] - AMT-191 for Fabry disease reported that all 11 patients in the Phase 1/2 trial exhibited elevated alpha-Gal A enzyme activity, with 6 patients successfully withdrawn from enzyme replacement therapy [18] - AMT-260 for mesial temporal lobe epilepsy showed promising initial data with a reduction in seizure frequency over the first 6 months [21] Market Data and Key Metrics Changes - The company is actively assessing ex-U.S. opportunities, evaluating priority markets based on epidemiology, regulatory pathways, pricing, and reimbursement landscapes [24] - The market for AMT-191 in Fabry disease is positioned to compete against chronic enzyme replacement therapies, highlighting the potential advantage of a one-time genetic approach [25] Company Strategy and Development Direction - The company remains focused on engaging with regulatory authorities to define the most appropriate path forward for AMT-130 and advancing pipeline programs with discipline [31] - The strategy includes pursuing named patient and early access program opportunities in rare diseases outside of the U.S. to enable access to therapies ahead of formal reimbursement decisions [24] - The company aims to leverage the Enroll-HD database to strengthen study designs for Phase 3 trials and minimize patient burden [48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength and durability of AMT-130 data and the commitment to the Huntington's disease community [10] - The urgency in the Huntington's disease community is acknowledged, with a strong belief that gene therapy can meaningfully change disease trajectories [32] - Management is committed to working with the FDA to explore regulatory flexibility for rare diseases [9] Other Important Information - The company plans to request a Type B meeting in the second quarter of 2026 to discuss potential Phase 3 study design approaches [16] - The company is preparing to present a manuscript with the complete results of the three-year analysis in a peer-reviewed medical journal later this year [17] Q&A Session Summary Question: Are there any paths to push your agenda beyond traditional FDA channels? - The company is exploring opportunities outside the U.S. and believes advocacy from the patient community is critical in educating elements outside the FDA [36] Question: Was morbidity associated with procedures involving burr holes a major sticking point? - The company has a strong safety profile and has not seen disease or clinical safety events associated with AMT-130 since December 2022 [44] Question: What are the different scenarios for a potential Phase III design? - It is premature to discuss specifics, as the design is still being defined in discussions with the FDA [58] Question: Why is the FDA requiring a sham control trial? - The FDA seeks to minimize potential bias, and while the company believes in the robustness of the natural history data, they acknowledge the FDA's preference for sham-controlled studies [96]